Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-29
Target enrollment:
Participant gender:
Summary
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD.
The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.